Emtricitabine - Gilead Sciences
Alternative Names: 524W91; BW-524W91; Coviracil; Emtriva; FTCLatest Information Update: 05 Jan 2022
At a glance
- Originator Emory University
- Developer Gilead Sciences
- Class Antiretrovirals; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
- Mechanism of Action DNA polymerase beta inhibitors; DNA polymerase gamma inhibitors; DNA polymerase I inhibitors; DNA polymerase II inhibitors; HIV reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV infections
- No development reported Hepatitis B
Most Recent Events
- 06 Jan 2020 No development reported - Phase-II for HIV infections (In adolescents, In children, In infants) in South Africa (PO)
- 05 Dec 2018 Gilead offered Japan Tobacco to terminate the exclusive licenses for HIV drugs in Japan
- 27 Aug 2018 Japan Tobacco and Gilead sign a letter of intent to initiate discussion to terminate license agreement for HIV drugs in Japan